<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004789</url>
  </required_header>
  <id_info>
    <org_study_id>199/11887</org_study_id>
    <secondary_id>UTMB-398</secondary_id>
    <nct_id>NCT00004789</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate the efficacy and safety of heme arginate in the treatment of 20&#xD;
      patients with acute attacks of porphyria.&#xD;
&#xD;
      II. Evaluate the efficacy and safety of heme arginate in preventing frequent exacerbations of&#xD;
      acute porphyria in up to 15 patients.&#xD;
&#xD;
      III. Estimate the lowest effective dose of heme arginate (0.3, 1.0, or 3.0 mg/kg) in reducing&#xD;
      porphyrin precursors in 12 stable patients with acute intermittent porphyria in remission.&#xD;
&#xD;
      IV. Evaluate the safety and efficacy of tin mesoporphyrin used in combination with heme&#xD;
      arginate in reducing porphyrin precursors in 12 stable patients with acute intermittent&#xD;
      porphyria in remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This project involves 4 studies: an unblinded multicenter treatment study,&#xD;
      an unblinded prevention study, a controlled dose-ranging study, and a controlled drug&#xD;
      combination dose-ranging study.&#xD;
&#xD;
      In the treatment study, participants with acute attacks of porphyria receive intravenous heme&#xD;
      arginate daily for 4 days. Treatment may be extended to 7 days in patients with severe&#xD;
      attacks and slow recovery; these data are analyzed separately.&#xD;
&#xD;
      In the prevention study, participants receive weekly infusions of heme arginate for 6 months.&#xD;
      Treatment may be extended in selected cases; these data are analyzed separately. If an acute&#xD;
      attack occurs, patients are treated with a standard course of heme arginate. Participants are&#xD;
      followed weekly for 6 months after preventive treatment.&#xD;
&#xD;
      In the dose-ranging study, 4 groups of 3 patients are randomly assigned to standard and&#xD;
      low-dose heme arginate infusions, administered daily for 4 days. After a washout of 4-12&#xD;
      weeks, patients are crossed to a second dose. In 2 of the 4 groups, patients cross between&#xD;
      heme arginate and a normal saline control.&#xD;
&#xD;
      In the combination dose-ranging study, 4 groups of 3 patients are randomly assigned to 1 of 2&#xD;
      doses of tin mesoporphyrin. After a 4-12 week washout, these patients are crossed to a&#xD;
      standard or low-dose heme arginate infusion. After a second 4-12 week washout, patients are&#xD;
      given a combination infusion of tin mesoporphyrin followed by heme arginate.&#xD;
&#xD;
      All participants are given a special diet to prevent fluctuations in porphyrin precursors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1993</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>59</enrollment>
  <condition>Porphyria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heme arginate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tin mesoporphyrin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Well-documented acute porphyria, i.e.: Acute intermittent porphyria Variegate&#xD;
             porphyria Hereditary coproporphyria&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  No pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Elmo Anderson</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>acute porphyria</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyrias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

